- Home
- RCUS vs AGO Comparison
RCUS vs AGO Comparison
Compare RCUS & AGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RCUS | AGO |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.0B |
| IPO Year | 2018 | 2003 |
Fundamental Metrics
Financial Performance| Metric | RCUS | AGO |
|---|---|---|
| Price | $17.47 | $74.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 15 | 3 |
| Target Price | $41.00 | ★ $91.00 |
| AVG Volume (30 Days) | ★ 2.4M | 315.8K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 2.08% |
| EPS Growth | N/A | ★ 49.34 |
| EPS | N/A | ★ 4.55 |
| Revenue | $247,000,000.00 | ★ $1,110,000,000.00 |
| Revenue This Year | N/A | $6.21 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.13 |
| Revenue Growth | N/A | ★ 27.29 |
| 52 Week Low | $17.43 | $67.24 |
| 52 Week High | $31.74 | $92.40 |
Technical Indicators
Market Signals| Indicator | RCUS | AGO |
|---|---|---|
| Relative Strength Index (RSI) | 34.56 | 63.26 |
| Support Level | N/A | $73.73 |
| Resistance Level | $19.63 | $76.96 |
| Average True Range (ATR) | 0.95 | 1.53 |
| MACD | 0.16 | 0.37 |
| Stochastic Oscillator | 10.96 | 86.27 |
Price Performance
Historical ComparisonAbout RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
About AGO Assured Guaranty Ltd.
Assured Guaranty Ltd. provides credit protection products to the United States and international public finance and structured finance markets and manages assets across collateralized loan obligations as well as opportunity funds and liquid funds that build on its corporate credit, asset-based finance, municipal, and healthcare experience. The company operates in two segments: the Insurance segment and the Asset Management segment. The majority of the revenue earned by the company is from the Insurance segment.